Day One Biopharmaceuticals (DAWN) Equity Ratio (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Equity Ratio for 4 consecutive years, with 0.87 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 0.7% to 0.87 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.87, a 0.7% increase, with the full-year FY2025 number at 0.87, up 0.7% from a year prior.
- Equity Ratio was 0.87 for Q4 2025 at Day One Biopharmaceuticals, down from 0.88 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2022 to a low of 0.77 in Q2 2024.
- A 4-year average of 0.91 and a median of 0.92 in 2023 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: fell 18.96% in 2024, then grew 15.91% in 2025.
- Day One Biopharmaceuticals' Equity Ratio stood at 0.95 in 2022, then fell by 3.12% to 0.92 in 2023, then decreased by 6.39% to 0.86 in 2024, then rose by 0.7% to 0.87 in 2025.
- Per Business Quant, the three most recent readings for DAWN's Equity Ratio are 0.87 (Q4 2025), 0.88 (Q3 2025), and 0.89 (Q2 2025).